64Cu-TLX592 Phase I Safety, PK, Biodistribution and Dosimetry Study (CUPID Study)
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase 1 trial of TLX592, a humanised, engineered monoclonal antibody HuX592r
conjugated with a DOTA chelator and radiolabelled with 64Cu (64Cu-TLX592). TLX592 is being
developed as a PSMA-targeting antibody to be radiolabelled with a therapeutic radiosotope for
the treatment of PSMA-expressing tumours, therefore this study has been designed to assess
the safety and tolerability, pharmacokinetics, whole body biodistribution and radiation
dosimetry of 64Cu-TLX592.